中文名称: | 盐酸齐拉西酮水合物 | ||||
---|---|---|---|---|---|
英文名称: | Ziprasidone hydrochloride monohydrate | ||||
别名: | 盐酸齐拉西酮; 5-(2-(4-(1,2-苯并异噻唑-3-基)-1-哌嗪基)乙基)-6-氯-1,3-二氢-2(1H)-吲哚-2-酮盐酸盐; 5-(2-(4-(1,2-苯并异噻唑-3-基)-1-哌嗪基)乙基)-6-氯-1,3-二氢-2(1H)-吲哚-2-酮; 齐哌西酮 CP 88059 hydrochloride monohydrate | ||||
CAS No: | 138982-67-9 | 分子式: | C21H21ClN4Os.HCl.H2O | 分子量: | 467.41 |
CAS No: | 138982-67-9 | ||||
分子式: | C21H21ClN4Os.HCl.H2O | ||||
分子量: | 467.41 |
基本信息
产品编号: |
Z10054 |
||||
产品名称: |
Ziprasidone hydrochloride monohydrate |
||||
CAS: |
138982-67-9 |
储存条件 |
粉末 |
2-8℃(避光) |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
6个月 |
||
分子量 |
467.41 |
-20℃ |
1个月 |
||
化学名: |
5-(2-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one hydrochloride hydrate |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
25 mg/mL (53.49mM; Need ultrasonic) |
|||
Ethanol |
|
||||
Water |
Insoluble |
||||
体内(现配现用): |
请依序添加每种溶剂:10% DMSO→40% PEG300→5% Tween-80 →45% saline Solubility: ≥ 2.5 mg/mL (5.35mM); Clear solution |
||||
此⽅案可获得 ≥ 2.5 mg/mL (5.35mM,饱和度未知) 的澄清溶液。 以 1mL ⼯作液为例,取 100μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中,混合均匀;向上述体系中加⼊ 50μL Tween-80,混合均匀;然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。 |
|||||
请依序添加每种溶剂:10% DMSO→90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.35mM); Suspended solution; Need ultrasonic |
|||||
此⽅案可获得 2.5 mg/mL (5.35mM) 的均匀悬浊液,悬浊液可⽤于⼝服和腹腔注射。以 1mL ⼯作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中,混合均 匀。 |
|||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.1394mL |
10.6972mL |
21.3945mL |
5mM |
0.4279mL |
2.1394mL |
4.2789mL |
10mM |
0.2139mL |
1.0697mL |
2.1394mL |
生物活性
产品描述 |
一种抗精神病药物,是具有口服活性的 5-HT (serotonin) 和多巴胺受体(dopamine receptor) 拮抗剂的联合用药。 |
||||
靶点 |
Rat 5-HT1A Receptor 3.4nM |
human 5-HT1A Receptor 2.5nM |
Rat 5-HT2A 0.42nM |
Rat D2 Receptor 4.8nM |
|
体外研究 |
Ziprasidone is a 5-HT1A receptor agonist and an antagonist at 5-HT2A, 5-HT2C and 5-HT1B/1D receptors. Ziprasidone has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes. |
||||
体内研究 |
Ziprasidone (20 mg/kg; p.o.; daily for 7 weeks) gains significantly less weight, has a lower level of physical activity, showed a higher resting energy expenditure, and displays a greater capacity for thermogenesis when subjected to cold. |
||||
Animal Model: |
Eight-week-old female Sprague-Dawley rats weighing 200 to 250 g |
||||
Dosage: |
20 mg/kg |
||||
Administration: |
P.o.; daily for 7 weeks |
||||
Result: |
Gained significantly less weight, had a lower level of physical activity, showed a higher resting energy expenditure, and displayed a greater capacity for thermogenesis when subjected to cold |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )